Matrix · Membrane-Controlled · Osmotic Pump · Pulsatile — Full-spectrum SR/CR formulation services from preformulation to BE study and NDA submission in China
Generic SR/CR formulation development is significantly more complex than conventional immediate-release products. The intricacy of release mechanisms demands deep technical expertise and systematic formulation capability.
Hydrophilic gel matrix (HPMC/PEO-based), insoluble matrix, and erodible matrix. Ideal for once-daily oral solids with stable, reproducible drug release.
Pellet film-coating for controlled release, multi-unit pellet systems (MUPS), enteric coating. Precise and tunable release profiles, well suited for combination SR formulations.
Single/dual-chamber osmotic tablets, push-pull osmotic pumps. Zero-order release kinetics independent of GI conditions — represents the highest technical barrier in SR/CR technology.
Time- and site-specific drug delivery systems for chronopharmacological needs. Includes delayed-burst combinations and colonic-targeted pulsatile drug release designs.
From reference listed drug (RLD) reverse engineering to final NDA approval — six tightly integrated phases to ensure development quality and regulatory efficiency.
Formulation composition analysis, release mechanism study, CQA identification
API characterization, excipient compatibility, formulation design & risk assessment
Dissolution curve modeling, DOE process optimization, lab-to-pilot scale-up
Multi-pH dissolution profile f₂ comparison, impurity & assay method validation
Fasting/fed bioequivalence study design, pre-BE strategy, clinical CRO coordination
CTD dossier writing, responses to CDE queries, on-site inspection support
15+ years of focused expertise in oral SR/CR formulation development — mastering the complete technical chain from lab-scale R&D to GMP pilot manufacturing.
Comprehensive RLD profiling including formulation composition, release mechanism, and CQA characterization. QbD-driven QTPP (Quality Target Product Profile) development to define the precise formulation design space for generic product development. Successfully applied across multiple SR/CR approved products.
Multi-pH f₂ factor evaluation framework combined with IVIVC (in vitro–in vivo correlation) modeling to predict BE outcomes and reduce clinical BE failure risk. Supports Level A/B/C IVIVC model building and regulatory submissions.
Systematic DoE methodology to optimize SR coating formulation variables and process parameters for precise release control. Full design space workflow including Plackett-Burman screening, response surface methodology (RSM), and multi-objective optimization.
Dissolution methods at pH 1.2, 4.5, 6.8 and QC media with alcohol dose dumping (ADD) assessment. Fully compliant with NMPA and FDA requirements for SR/CR formulation in vitro release testing.
Systematic characterization of BCS classification-determining parameters: particle size distribution (PSD), polymorphism (XRD), solubility/pH dependency, logP, and pKa. Directly guides SR/CR formulation strategy selection.
Step-wise scale-up from lab 1 kg to pilot 30 kg batches. Covers wet granulation, dry granulation, fluid bed coating, hot melt extrusion (HME), and other critical unit operations. Ensures process transferability and inter-batch consistency.
Critical quality attributes, evaluation challenges, and technical strategies for each SR/CR formulation type in China's generic drug development pathway.
| System Type | Representative Products | Key Quality Attributes | Key Challenges | Technical Solutions |
|---|---|---|---|---|
| Matrix | Metformin ER, Gliclazide MR, Felodipine ER | Dissolution profile, matrix integrity, erosion behavior | Burst release control at early phase; complete release at end stage | Polymer grade/viscosity screening + porogen adjustment + DoE matrix ratio optimization |
| Membrane-Coated Pellets | Omeprazole enteric capsules, Pantoprazole DR, Mesalazine ER granules | Coating uniformity, acid resistance, release lag time | Multi-layer coating uniformity; multi-pH release profile matching | Fluid bed bottom-spray coating + coating weight gradient study + in-line NIR monitoring |
| Osmotic Pump | Nifedipine GITS, Glipizide GITS, Venlafaxine ER capsules | Orifice diameter, semipermeable membrane integrity, zero-order release slope | Laser drilling precision; semipermeable membrane formula; drug solubility matching with push layer | Coating weight optimization + osmotic pressure modulation in push layer + laser drilling validation |
| Pulsatile | Eszopiclone pulsatile tablet, Meloxicam chronotherapeutic tablet | Lag time accuracy, burst-release completeness | Inter-batch lag time consistency; GI variability across individuals | Bilayer tablet technology + disintegrant type/level screening + multilayer compression optimization |
From RLD reverse engineering to NDA submission — no fragmented outsourcing. Pharmaceutical sciences, BE studies, and regulatory affairs are managed as a unified program, minimizing communication overhead and handover risk.
15+ years focused on oral solid SR/CR formulation development, with full command of matrix, membrane-controlled, and osmotic pump technology routes. Reverse engineering + QbD development methodology validated across multiple approved projects.
R&D expenditure consistently exceeds 80% of annual revenue. Well-equipped analytical labs and GMP pilot manufacturing facilities. Continuous technical iteration ensures cutting-edge and reliable development solutions.
Supports contract research (CRO), equity co-development, and other collaboration structures. Customized development plans based on client needs to reduce upfront investment risk and align incentives.
Each critical milestone in the development pathway has dedicated professional support. Click below to explore individual service capabilities.
Systematic RLD profiling: formulation composition, release mechanism, and CQA characterization. QTPP establishment to guide generic formulation development with precision.
Explore Preformulation Capabilities →QbD-driven SR/CR formulation development — matrix polymer screening, dissolution curve modeling, DoE process parameter optimization. Full chain from lab-scale to pilot scale-up.
Explore Formulation Capabilities →Multi-pH dissolution f₂ factor evaluation, comparative dissolution profiling, impurity and assay method validation. Fully compliant with NMPA SR/CR in vitro release requirements.
Explore Analytical Capabilities →Fasting/fed BE study protocol design, pre-BE strategy formulation, clinical CRO coordination. IVIVC-based BE risk prediction to reduce formal BE failure probability.
Explore Clinical Research Capabilities →Full CTD dossier preparation, with focus on Module 2 (QOS) and Module 3 (Quality). CDE query response strategy and 15+ years of regulatory experience to streamline the submission pathway.
Explore Regulatory Affairs →From RLD listing application to GMP on-site inspection. Comprehensive NDA submission support for generic drug development in China. CDE query management, pre-inspection preparation, and communication strategy.
Explore Full Regulatory Support →SR/CR generic development is significantly more complex than conventional immediate-release (IR) equivalents. Beyond standard dissolution comparison (typically 3–4 pH media), it requires demonstrating equivalence in release mechanism, assessing alcohol dose dumping (ADD) risk, and characterizing food effect influence. SR/CR formulations are also more sensitive to formulation and process variables, making BE failure more likely. We strongly recommend thorough in vitro dissolution matching during the formulation phase to reduce clinical risk.
BE failure typically stems from: ① inadequate dissolution profile matching with the RLD (f₂ < 50 or significant deviation); ② poor IVIVC — in vivo release behavior deviates substantially from in vitro predictions; ③ SR polymer type/grade/level differences causing in vivo discordance; ④ dissolution profile drift after process scale-up. We recommend early investment in multi-pH dissolution studies and Level A IVIVC modeling to systematically reduce clinical BE risk.
Timeline varies by product complexity: pharmaceutical development typically takes 12–18 months (including pilot scale-up); BE studies require 6–8 months; NDA review by CDE takes 12–18 months. Total timeline: approximately 2.5–4 years. Complex systems such as osmotic pumps require longer pharmaceutical development phases. Early initiation and built-in buffer at each phase are strongly recommended.
We offer three models: ① Full-scope contract R&D (CRO) — milestone-based billing, Taikomed assumes all pharmaceutical and regulatory responsibilities; ② Module-based outsourcing — e.g., formulation development only, or quality research only; ③ Equity co-development — technology-for-equity collaboration with shared post-approval revenue. Specific arrangements are negotiated based on product characteristics and client requirements.
As of today, very few osmotic pump SR/CR generics have passed China's consistency evaluation (notable examples: Nifedipine GITS, Glipizide GITS). This reflects the high technical barrier of osmotic pump technology — laser drilling precision, semipermeable membrane formulation, and push-pull layer matching present extreme development challenges. Taikomed has systematic osmotic pump development capabilities and multi-project experience in this domain.
Strongly recommended in the following scenarios: ① First-time SR/CR generic development — complex release behavior that in vitro data alone cannot fully predict in vivo performance; ② Multiple candidate formulations to screen — pre-BE rapidly identifies the optimal formulation, avoiding wasted resources on wrong directions; ③ BCS Class II or IV APIs — solubility and permeability complexity increases BE uncertainty. Pre-BE typically involves 12–24 subjects to confirm the formal BE protocol, at a fraction of the cost of a failed BE study. Taikomed provides end-to-end pre-BE support from protocol design to clinical CRO management.
Multi-pH dissolution comparison (typically 3–4 media) is the cornerstone technical requirement for SR/CR generic evaluation. When f₂ < 50, systematically trace back formulation variables — SR polymer type, level, and process parameters — to identify the root cause. Verify that the dissolution method has sufficient discriminatory power. Then apply DoE methodology to re-optimize the formulation. Taikomed has a systematic troubleshooting protocol for f₂ non-compliance, combining IVIVC modeling with formulation optimization, with documented success across multiple products.
For SR/CR generics, Module 2 (QOS) must compellingly demonstrate release mechanism equivalence and comparative CQA data. Module 3 (Quality) requires complete multi-pH dissolution profile comparison data, alcohol dose dumping (ADD) assessment, and a well-documented development risk assessment and design space. Common CDE query areas include: insufficient mechanistic justification for release profile similarity, and inadequate comparability data for the scale-up batches. Taikomed's regulatory team has in-depth knowledge of CDE review focus areas for SR/CR submissions and provides full-scope support from dossier writing to query response.
Contact our technical team today for a complimentary product feasibility assessment and development strategy consultation. 15 years of SR/CR expertise, trusted by 100+ pharmaceutical companies.
📞 Call: +86-29-81107958 ✉️ Email Inquiry